Beam Tx (BEAM) Price to Earnings Ratio

Corporate emblem and logo of Beam Therapeutics Inc (BEAM)

The patent monopoly on the treatment of genetic pathologies provides Beam Therapeutics Inc. (BEAM) with a stable income stream, which is supported by the company's estimated P/E. The partnership with Pfizer accelerates the development of precision therapies, while a neutral geopolitical environment in the US and EU ensures business stability. The current metric stands at -22.10, allowing for an objective comparison of the share price against the issuer's actual earnings.

Beam Tx (BEAM) - Price to Earnings Ratio from 07/04/2022 to 11/16/2026

Comprehensive metric breakdowns and analytics for Beam Therapeutics Inc (BEAM)

Comprehensive company analysis:Beam Therapeutics - BEAM
Flagship merchandise of Beam Therapeutics

The P/E ratio compares a business's market value to its net income, allowing investors to determine the extent of an asset's overvaluation and estimate the investment's payback period. By analyzing the quarterly P/E of Beam Therapeutics Inc. (BEAM), an investor can see how risks of technological nationalism and patent disputes impact the capitalization of Beam Therapeutics Inc. (BEAM), which is critical for verifying the fundamental stability of this biopharmaceutical issuer.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Sarepta Therapeutics, Inc. (SRPT) - P/E Multiple|TWST (twistbioscience.com) - P/E Multiple|10x Genomics, Inc. (TXG) - Business Payback Period|Price to Earnings Ratio NTLA (Intellia Therapeutics, Inc.)|STOK - Market Cap to Earnings|Price to Earnings Ratio biolifesolutions.com BLFS|Business Payback Period Wave Life Sciences Corp (WVE)|MAZE - Price to Earnings Ratio|Company Value to Net Income SION (Sionna Therapeutics Inc)|PRME: P/E Multiple|Taysha - Company Value to Net Income|Price to Earnings Ratio uniQure NV|Price to Earnings Multiple MGTX (MeiraGTx PLC)|Price to Earnings Ratio RGNX (regenxbio.com)|Solid Biosciences Inc. - Price to Earnings Multiple|Price to Earnings Ratio Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio